tradingkey.logo

BRIEF-Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

ReutersFeb 5, 2025 1:38 PM

- VistaGen Therapeutics Inc VTGN.O:

  • VISTAGEN RECEIVES U.S. PATENT FOR AV-101 TO TREAT NEUROPATHIC PAIN

  • VISTAGEN THERAPEUTICS-PLANS TO SEEK POTENTIAL STRATEGIC COLLABORATIONS TO FURTHER ADVANCE POTENTIAL CLINICAL DEVELOPMENT, COMMERCIALIZATION OF AV-101

  • VISTAGEN THERAPEUTICS INC - PATENT WILL NOT EXPIRE UNTIL AT LEAST 2034

Source text: ID:nBw3rMzwHa

Further company coverage: VTGN.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI